TCL Archive DeVita Resigns As No. 2 At Sloan-Kettering To “Pursue Clinical Research,” Hospital Says May 31, 1991
TCL Archive FDA approves a new cancer drug, Vidaza, and two sNDAs, without going to ODAC. A date with ODAC may signal a weak case for drug approval, recent approval data indicate. May 28, 2004
TCL Archive Special Report on Cancer Centers: Three cancer centers win $9 million core grants, 11 of 13 competitors cut due to NCI budget shortfall. January 16, 2004
